BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 16640847)

  • 21. The immunological response of Thai infants to haemophilus influenzae type B polysaccharide-tetanus conjugate vaccine co-administered in the same syringe with locally produced diphtheria-tetanus-pertussis vaccine.
    Kerdpanich A; Hutagalung Y; Watanaveeradej V; Bock HL; Steinhoffmd M
    J Med Assoc Thai; 2007 Jul; 90(7):1330-6. PubMed ID: 17710973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine.
    Nolan T; Altmann A; Skeljo M; Streeton C; Schuerman L
    Vaccine; 2004 Nov; 23(1):14-20. PubMed ID: 15519702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB).
    Bar-On ES; Goldberg E; Fraser A; Vidal L; Hellmann S; Leibovici L
    Cochrane Database Syst Rev; 2009 Jul; (3):CD005530. PubMed ID: 19588375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
    Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Four is better than nine. a combined diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine for routine immunization in Malaysia.
    Wong SL; Soosai P; Teoh YL; Han HH; Lefevre I; Bock HL
    Southeast Asian J Trop Med Public Health; 2008 May; 39(3):474-83. PubMed ID: 18564687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
    Habermehl P; Leroux-Roels G; Sänger R; Mächler G; Boutriau D
    Hum Vaccin; 2010 Aug; 6(8):640-51. PubMed ID: 20697200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
    Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
    Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A combined liquid Hib (PRP-OMPC), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: controlled studies of immunogenicity and reactogenicity.
    Nolan T; Hogg G; Darcy MA; Skeljo M; Carlin J; Boslego J
    Vaccine; 2001 Feb; 19(15-16):2127-37. PubMed ID: 11228385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical experience with DTPw-HBV and DTPw-HBV/Hib combination vaccines.
    Prymula R; Plisek S
    Expert Opin Biol Ther; 2008 Apr; 8(4):503-13. PubMed ID: 18352853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses.
    Heininger U; ; ; Sänger R; Jacquet JM; Schuerman L
    Vaccine; 2007 Jan; 25(6):1055-63. PubMed ID: 17049692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule.
    Chatterjee S; Rego SJ; D'Souza F; Bhatia BD; Collard A; Datta SK; Jacquet JM
    BMC Infect Dis; 2010 Oct; 10():298. PubMed ID: 20950457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth.
    Posuwan N; Wanlapakorn N; Vongpunsawad S; Sintusek P; Leuridan E; Van Damme P; Poovorawan Y
    Vaccine; 2020 Feb; 38(7):1643-1651. PubMed ID: 31948817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
    Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
    Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children.
    Sharma HJ; Yadav S; Lalwani SK; Kapre SV; Jadhav SS; Chakravarty A; Parekh SS; Palkar S; Bhardwaj SH; Namjoshi GS; Verma V
    Hum Vaccin; 2011 Apr; 7(4):451-7. PubMed ID: 21403463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of a combined DTPa-HB vaccine co-administered with Haemophilus influenzae type B conjugate vaccine (PRP-T) for primary and booster vaccinations.
    Bracco Neto H; Colucci A; Puccini RF; Farhat CK
    Braz J Infect Dis; 2005 Oct; 9(5):363-73. PubMed ID: 16410887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
    Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A
    Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections.
    Schmitt HJ; Knuf M; Ortiz E; Sänger R; Uwamwezi MC; Kaufhold A
    J Pediatr; 2000 Sep; 137(3):304-12. PubMed ID: 10969252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the immunogenicity and safety of pentavalent vaccine Quinvaxem in a compact prefilled auto-disabled (cPAD) injection system versus single-dose vials in healthy infants: a phase 3, open-label, randomized, parallel-group, non-inferiority study.
    Capeding MR; Alberto E; Versteilen A; Rauscher M; Bagchi P; Palacios PI
    Int J Infect Dis; 2016 May; 46():71-8. PubMed ID: 26923083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interchangeability of Quinvaxem during primary vaccination schedules: results from a phase IV, single-blind, randomized, controlled, single-center, non-inferiority study.
    Capeding MR; Jica C; Macura-Biegun A; Rauscher M; Alberto E
    Vaccine; 2014 Feb; 32(7):888-94. PubMed ID: 24176498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
    Tregnaghi M; Zambrano B; Santos-Lima E
    Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.